Clinical Drug Experience Knowledgebase

Criteria

Inclusion Criteria:

Written informed consent for this clinical trial (+ TR (translational research)) must be given according to ICH/GCP and national/local regulations
Written documentation of BRAF-like signature CC, including BRAFm and BRAFwt, as determined by the validated assay of Agendia
Written documentation of KRAS and BRAF mutational status.
Age > 18 years
Histologically proven and measurable (RECIST criteria v.1.1) metastatic adenocarcinoma of the colon not in a previously irradiated area, treated with at least one or two lines of standard of care therapy, including BRAF inhibitors, for advanced disease
WHO performance status of 0-1
Able and willing to undergo blood sampling for pharmacodynamic (PD) analysis;
Able and willing to undergo tumor biopsy prior to, during and upon treatment;
Life expectancy > 3 months allowing adequate follow up of toxicity evaluation and antitumor activity

Minimal acceptable safety laboratory values:

ANC > 1.5 x 109 /L
Platelet count > 100 x 109 /L
Hemoglobin > 6.0 mmol/L
Hepatic function as defined by serum bilirubin < 1.5 x ULN, ALAT and ASAT < 2.5 x ULN, or ALAT and ASAT < 5 x ULN in patients with liver metastases
Renal function as defined by serum creatinine < 1.5 x ULN
creatinine clearance > 50 ml/min (by Cockcroft-Gault formula)
Negative urine or serum pregnancy test (serum or urine) for female patients with childbearing potential

Exclusion Criteria:

Any treatment with investigational drugs, including BRAF inhibitors, within 28 days prior to receiving the first dose of investigational treatment
Symptomatic or untreated leptomeningeal disease
Symptomatic brain metastasis. Patients previously treated or untreated for these conditions that are asymptomatic in the absence of corticosteroid and anticonvulsant therapy (for at least 4 weeks) are allowed to enroll. Radiotherapy for brain metastasis must have been completed at least 6 weeks prior to start of study treatment. Brain metastasis must be stable with verification by imaging (e.g. brain MRI or CT completed at screening (<21 days before start of treatment) demonstrating no current evidence of progressive brain metastases). Patients are not permitted to receive enzyme inducing anti-epileptic drugs or corticosteroids.
Impairment of gastrointestinal (GI) function or GI disease (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, any condition inducing malabsorption, small bowel resection)
Other uncontrolled concomitant illness, including serious uncontrolled intercurrent infection
Known allergy or any other adverse reaction to any of the drugs or to any related compound
Women who are pregnant or breast feeding
Unreliable contraceptive methods. Both men and women enrolled in this trial must agree to use a reliable contraceptive method throughout the study (adequate contraceptive methods are: condom, sterilization, other barrier contraceptive measures preferably in combination with condoms) 9. Radio-, immuno- or chemotherapy within the last 4 weeks prior to receiving the first dose of investigational treatment. Palliative radiation (1x 8Gy) is allowed

10. Patients who have undergone any major surgery within the last 2 weeks prior to starting study drug or who would not have fully recovered from previous surgery 11. Uncontrolled infectious disease or known Human Immunodeficiency Virus HIV-1 or HIV-2 type patients 12. Patients with a known history of hepatitis B or C 13. Patients with cardiac comorbidities (myocardial infarct within 6 months of study start, NYHA class ≥ III, congestive heart failure or instable angina pectoris), uncontrolled hypertension (systolic blood pressure > 150 mm Hg and/or diastolic pressure > 90 mm Hg) or prolonged QT-interval (> 440 ms for men, > 460 ms for women) 14. Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or that may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for the study 15. Known hypersensitivity to study drug or excipients